SHR 0302 is a selective JAK1 inhibitor and China developed new chemical entity. Reistone is currently developing SHR 0302 globally in the field of Inflammatory Bowel Diseases (IBD) such as Ulcerative colitis (UC) and Crohn’s disease (CD), and Dermatology Diseases such as Atopic Dermatitis.
JAK inhibitors function by interfering with the JAK-STAT signaling pathway via blocking the Janus Kinase enzyme family which includes JAK1, JAK2, JAK3 and TYK2. Studies have shown that JAK1 inhibitors positively contribute to the effectiveness of anti-inflammatory therapies. However, the currently available pan-JAK inhibitors, may also inhibit JAK2 kinase, which contribute to the unwanted side-effect of lower hemoglobin, lymphocyte and neutrophil counts that could result in infection. Therefore, a highly selective JAK1 inhibitor may have an improved safety profile while targeting the anti-inflammatory effect. Selective JAK inhibitor is likely to become a benchmark for a new generation of JAK inhibitors in the future.
As an effective immune modulator and anti-inflammatory medicine, JAK inhibitor has proven its efficacy in treating rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis. Research into other autoimmune diseases such as systemic lupus erythematous is ongoing.